Profile data is unavailable for this security.
About the company
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
- Revenue in DKK (TTM)5.58m
- Net income in DKK-12.10m
- Incorporated2000
- Employees10.00
- LocationViroGates A/SBanevaenget 13BIRKEROED 3460DenmarkDNK
- Websitehttps://www.virogates.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elicera Therapeutics AB | 7.20m | -10.51m | 26.88m | 2.00 | -- | 1.44 | -- | 3.73 | -0.8289 | -0.8289 | 0.5677 | 0.8291 | 0.2937 | -- | 8.15 | 5,615,030.00 | -42.88 | -40.06 | -66.66 | -49.74 | -- | -- | -146.02 | -415.41 | -- | -- | -- | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Veg of Lund AB (publ) | 3.09m | -12.76m | 28.56m | 7.00 | -- | 1.06 | -- | 9.25 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
| Oncozenge AB | 0.00 | -10.19m | 30.03m | -- | -- | 2.51 | -- | -- | -1.36 | -1.36 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -55.57 | -- | -60.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 65.91 | -- | -- | -- |
| Pila Pharma AB | 937.71k | -6.36m | 33.40m | 1.00 | -- | 7.82 | -- | 35.62 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Orphazyme A/S | 0.00 | -26.05m | 37.06m | 1.00 | -- | 2.60 | -- | -- | -737.75 | -737.75 | 0.00 | 403.34 | 0.00 | -- | -- | 0.00 | -68.42 | -76.08 | -94.18 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -17.93m | 37.55m | -- | -- | 4.50 | -- | -- | -2.67 | -2.67 | 0.00 | 0.6404 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -- | -- | -170.65 | -- | -- | -- | -- | 20.60 | -- | -- | -- |
| ViroGates A/S | 5.58m | -12.10m | 38.69m | 10.00 | -- | 2.27 | -- | 6.93 | -6.12 | -6.12 | 1.61 | 2.64 | 0.2653 | 0.2654 | 3.15 | 558,300.00 | -57.47 | -46.58 | -63.01 | -52.09 | 78.83 | 77.91 | -216.66 | -238.01 | 8.56 | -23.89 | 0.2376 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 878.30k | -11.11m | 40.66m | 10.00 | -- | 11.30 | -- | 46.30 | -0.1837 | -0.1837 | 0.0136 | 0.0556 | 0.1016 | -- | 18.59 | 137,033.00 | -128.49 | -80.90 | -198.98 | -106.45 | -241.22 | -686.41 | -1,265.24 | -1,360.03 | -- | -217.55 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Peptonic Medical AB | 23.79m | -27.30m | 40.73m | 38.00 | -- | 0.8436 | -- | 1.71 | -0.0362 | -0.0362 | 0.0326 | 0.0491 | 0.3857 | 1.32 | -- | 976,789.50 | -44.25 | -46.02 | -67.60 | -60.85 | 43.90 | 54.26 | -114.74 | -139.38 | 0.7771 | -29.32 | 0.0912 | -- | -14.93 | 149.65 | -15.55 | -- | 14.43 | -- |
| PCI Biotech Holding ASA | 1.91m | -12.99m | 42.73m | 7.00 | -- | 1.71 | -- | 22.35 | -0.5443 | -0.5443 | 0.0801 | 1.05 | 0.0556 | -- | 0.6848 | -- | -37.78 | -36.44 | -41.97 | -40.14 | -- | -- | -679.43 | -1,055.43 | -- | -- | 0.0081 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Chosa Oncology AB | 46.79k | -15.35m | 42.83m | -- | -- | 3.84 | -- | 915.34 | -0.3524 | -0.3524 | 0.0013 | 0.2684 | 0.003 | -- | 0.013 | -- | -96.68 | -51.96 | -178.66 | -61.92 | -- | -- | -32,798.63 | -708.47 | -- | -97.97 | -- | -- | -98.21 | -- | 28.33 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 771.05k | -27.06m | 43.50m | 13.00 | -- | 1.60 | -- | 56.41 | -0.3818 | -0.3818 | 0.0115 | 0.1882 | 0.0093 | -- | 5.74 | 92,538.46 | -32.61 | -20.19 | -35.38 | -20.97 | 247.55 | -- | -3,509.81 | -4,853.45 | -- | -- | -- | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Diagonal Bio AB | 14.74k | -7.48m | 46.52m | 4.00 | -- | 0.3316 | -- | 3,155.65 | -0.1982 | -0.1982 | 0.0004 | 0.3221 | 0.0007 | -- | 2.00 | 5,750.00 | -37.35 | -- | -44.49 | -- | -41,604.35 | -- | -50,769.57 | -- | 0.5105 | -104.20 | -- | -- | -88.67 | -- | 27.75 | -- | -- | -- |
| Combigene AB | 3.55m | -22.86m | 48.86m | 11.00 | -- | 0.6546 | -- | 13.75 | -1.80 | -1.80 | 0.28 | 5.88 | 0.0398 | -- | 2.63 | 504,000.00 | -25.58 | -13.00 | -26.56 | -14.58 | -- | -- | -643.33 | -58.77 | -- | -- | -- | -- | -79.24 | 268.58 | -479.27 | -- | -- | -- |
| Abera Bioscience AB | 0.00 | -10.72m | 50.97m | -- | -- | 13.25 | -- | -- | -1.24 | -1.24 | 0.00 | 0.391 | 0.00 | -- | -- | -- | -115.63 | -79.43 | -149.06 | -96.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.73 | -- | -- | -- |
| Odi Pharma AB (publ) | 524.53k | -2.54m | 51.21m | -- | -- | 39.24 | -- | 97.64 | -0.2608 | -0.2608 | 0.0538 | 0.1338 | 0.1084 | 1.22 | 6.98 | -- | -52.58 | -- | -95.24 | -- | -53.07 | -- | -484.96 | -- | 1.32 | -14.10 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
